|
市場調查報告書
生物標記的最新動向
Advances in Biomarkers
|
生物標記的最新動向 是由出版商Technical Insights, Inc.在2009年06月所出版的。
這份英文市場調查報告書價格從美金6500起跳。
本報告書內容包括：生物標記分析、藥物發現及臨床診斷中生物標記扮演的角色及全球開發動向等。內容綱要摘記如下：
第1章 實施概要
第2章 藥物發現之生物標記
- 藥物發現及新藥開發的生物標記方法
- 值得一提的技術創新
- 對小分子藥物亮綠燈，除此之外的藥物則亮紅燈
- 掌握藥物毒性
- 檢測蛋白質的困難度
- 代謝體學的明確願景及觀點
- 標的治療用的標的診斷個案研究
- 治療及合併診斷
- 抗EGFR治療相關廣泛研究
- HIV的多樣性
- 共同診斷
第3章 臨床診斷之生物標記
- 臨床診斷中生物標記的角色
- 更好的診斷重要性等同更好的治療
- 癌症領域的技術創新
- 癌症領域之外的技術創新
第4章 生物標記產業的策略性評價
第5章 專利的策略性評價及聯絡對象
第6章 決策支援資料庫
Abstract
This research service outlines the key global developments in the field of
biomarkers.
Table of Contents
1. EXECUTIVE SUMMARY
Macroscopic View of Biomarkers
- Go Biological with a Biomarker
- Types of Biomarkers
- Omics to Know-Omics Now
Scope and Methodology
- Scope and Segmentation of the Research Service
- Research Methodology
2. BIOMARKERS IN DRUG DISCOVERY
The Biomarker Method in Drug Discovery and Development
- Biomarkers May Relieve the Drug Discovery Bottleneck
- See Path to a Biomarker
Noteworthy Innovations
- Biomarker Serves as a Green Signal for a Small Molecule Drug and a Red
Alert for Another
- Stack of Biomarkers Aid in Understanding Drug Toxicity
- Proteins Find it Difficult to Remain Undetected
- A Clear Vision and View for Metabolomics
Case Studies of Targeted Diagnostics for Targeted Therapeutics
- Diagnostic as a Companion to Therapeutic
- Wealth of Research on Anti-EGFR Therapy
- HIV Takes Diversion and Tricks the Drug
- Companion Diagnostics Make a Footprint
3. BIOMARKERS IN CLINICAL DIAGNOSTICS
The Biomarker Role in Clinical Diagnostics
- Better Diagnostics is Equal to Better Treatment
- Noteworthy Innovations in Oncology
- Noteworthy Innovation in Nononcology Areas
4. STRATEGIC EVALUATION OF THE BIOMARKER INDUSTRY
Application Trend Analysis
- Biomarkers Research Direction
- Biomarkers Promise to Deliver Sooner in Oncology
AHP--Prioritization of Biomarker Technologies
- Definition of Criteria
- AHP Process and Computation for Goal Node and Level 0 Criteria
- AHP Process and Computation for Goal Node and Level 1 Criteria
- Final Priorities and Analyst Insights
Force Field Analysis
- Growth Drivers and Growth Inhibitors
- Strategies for Change
5. STRATEGIC EVALUATION OF PATENTS AND KEY CONTACTS
Strategic Evaluation of Patents
- World Biomarker IP Portfolio--Drug Discovery
- Key Patents in Oncology--Diagnostics--Pertaining to Developments in
Chapter 3.1
- Key Patents in Nononcology Areas--Diagnostics--Pertaining to Developments
in Chapter 3.1
Key Contacts and Appendix
6. DECISION SUPPORT DATABASE
Database Tables
- Government Investment in Biotechnology--World (2002 to 2012)
- Percent Government R&D Investment in Biotechnology--World (2002 to 2012)
- Global Pharmaceutical R&D Expenditure (2002 to 2012)
- Global Percentage Pharmaceutical R&D Expenditure (2002 to 2012)
|
